FGH Biotech
2011
FOUNDED
PRIVATE
STATUS
Later Stage VC
LATEST DEAL TYPE
(In Progress)
$2.08M
LATEST DEAL AMOUNT
2
INVESTORS
Description
Developer of novel drugs designed to treat metabolic disorders. The company's drugs target the master regulatory switch for fat production, known as sterol regulatory element-binding proteins (SREBP), enabling physicians to treat obesity, non-alcoholic fatty liver disease, type II diabetes and lipid disorders.
Website
Ownership Status
Privately Held (backing)
Financing Status
Pending Transaction (VC)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 414 Thamer Circle
- Houston, TX 77024
- United States
+1 (713) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore FGH Biotech’s full profile, request a free trial.
FGH Biotech Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 06-Sep-2017 | $2.08M | 00.000 | In Progress | Generating Revenue | |
| 3. Early Stage VC | Completed | Generating Revenue | ||||
| 2. Angel (individual) | 06-Nov-2015 | Cancelled | Generating Revenue | |||
| 1. Grant | 01-Jan-2014 | $1.84M | Completed | Generating Revenue |
FGH Biotech Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | |||
| BCM Technologies | Venture Capital | Minority | 000 0000 | 000000 0 |
FGH Biotech Executive Team (4)
FGH Biotech Board Members (3)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Adam Kuspa | FGH Biotech | Board Member | 000 0000 | |
| Joe Wakil | FGH Biotech | President & Board Member | 000 0000 | |
| Salih Wakil | FGH Biotech | Co-Founder & Board Member | 000 0000 |